Page last updated: 2024-11-13

prajmaline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Prajmaline: A derivative of the rauwolfia alkaloid AJMALINE. It is an anti-arrhythmia agent but may cause liver damage. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135398003
MeSH IDM0017433

Synonyms (3)

Synonym
n-propylajmaline
prajmaline
prajmalium

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" In the study population with normal metabolic status the two oral formulations proved to be bioequivalent with regard to the pharmacokinetic parameters Cmax, AUC(0-Tlast), AUC(0-infinity) and Ae(24h)."( Pharmacokinetics and relative bioavailability of prajmalium bitartrate after single oral dosing.
Bondy, S; Breuel, HP; Dahmen, W; Hausleiter, HJ; Weimann, HJ, 1991
)
0.28
" None of the Spearman rank correlation coefficients between the pharmacokinetic parameters of N-PAB with age, plasma albumin/globulin-quotient, plasma creatinine and cholin-esterase were significant."( Pharmacokinetics of n-propyl-ajmaline-bitartrate in elderly patients with ventricular ectopic activity.
Achtert, G; Elfner, R; Hausleiter, HJ; Heene, DL; Lentz, A,
)
0.13
" For definition of the drug's pharmacokinetic properties plasma concentrations were determined."( [Pharmacokinetics and Antiarrhythmic effects of Prajmalium Bitartrate].
Bussmann, WD; Trompler, AT; Woodcock, BG, 1983
)
0.27
" The terminal plasma elimination half-life (beta-phase) was in the range of 4 to 6 hours."( [Pharmacokinetics and biotransformation of N-propylajmaline hydrogen tartrate in man].
Achtert, G; Beubler, E; Hausleiter, HJ; Khan, MA; Kukovetz, WR,
)
0.13

Bioavailability

ExcerptReferenceRelevance
"Pharmacokinetics and relative bioavailability of the marketed prajmalium bitartrate tablet (Neo-Gilurytmal, CAS 2589-47-1) compared to an oral solution were investigated in an open, randomized, single-dose two-fold crossover study in 20 healthy male volunteers."( Pharmacokinetics and relative bioavailability of prajmalium bitartrate after single oral dosing.
Bondy, S; Breuel, HP; Dahmen, W; Hausleiter, HJ; Weimann, HJ, 1991
)
0.28
" The bioavailability was 78%."( [Pharmacokinetics and biotransformation of N-propylajmaline hydrogen tartrate in man].
Achtert, G; Beubler, E; Hausleiter, HJ; Khan, MA; Kukovetz, WR,
)
0.13
"Prajmaline, the semisynthetic propyl derivative of ajmaline, shows a much better bioavailability when compared with the Rauvolfia alkaloid ajmaline."( The structure of the ring-opened N beta-propyl-ajmaline (Neo-Gilurytmal) at physiological pH is obviously responsible for its better absorption and bioavailability when compared with ajmaline (Gilurytmal).
Hinse, C; Stöckigt, J, 2000
)
0.31

Dosage Studied

ExcerptRelevanceReference
" Thus, neogilurythmal is low toxic and produces no adverse effects when given in the definite dosage range."( [Anti-arrhythmic effectiveness of neogilurhythmal in extrasystolic arrhythmia].
Imnadze, GN; Kobuliia, BG; Maĭsuradze, MZ; Mindadze, KA; Saatashvili, GA, 1992
)
0.28
" The first dosage of 4 X 5 mg/d has been increased by 5 mg in three steps of three days to a level of 4 X 20 mg/d."( [Dose-effect relation of N-prajmalium bitartrate with control of plasma levels].
Achtert, G; Elfner, R; Engels, I; Hausleiter, HJ; Heene, DL; Kollmeier, W; Lentz, A; Westphal, E, 1986
)
0.27
" After twelve days (total dosage 510 mg N-propyl-ajmaline) acute severe intrahepatic cholestasis and aplastic anemia developed."( [Intrahepatic cholestasis and aplastic anemia following administration of prajmaline].
Borchard, F; Gottesbüren, H; Lenzen, R; Strohmeyer, G; Wienbeck, M, 1988
)
0.27
" Five subjects were treated for 7 days with a daily N-propylajmaline dosage of either 60 mg or 20 mg."( Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation.
Achtert, G; Eichelbaum, M; Hausleiter, HJ; Moon, CH; Zekorn, C, 1985
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (83)

TimeframeStudies, This Drug (%)All Drugs %
pre-199052 (62.65)18.7374
1990's26 (31.33)18.2507
2000's5 (6.02)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials13 (14.77%)5.53%
Reviews0 (0.00%)6.00%
Case Studies19 (21.59%)4.05%
Observational0 (0.00%)0.25%
Other56 (63.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]